Sector News

Ranbaxy India head Rajeev Sibal latest to quit

July 8, 2015
Life sciences
In a continuing spate of high-level executive exits, Rajeev Sibal, head of India operations at Ranbaxy, has put in his papers. Sibal — a pharma industry veteran — is expected to join drug company Lupin later this month, where he will be responsible for India and other emerging markets, sources told TOI. 
 
With Sibal’s exit, the only other senior executive left behind from erstwhile Ranbaxy — which was acquired by Sun Pharma — is Subodh Marwaha, head consumer (OTC), besides the MD, Arun Sawhney. Sun Pharma, run by billionaire businessman Dilip Shanghvi, is executing a massive manpower restructuring in the company he acquired recently. The rejig is expected to involve 150-odd senior executives and flatten roles in even R&D and certain manufacturing facilities. 
 
Sibal, who is an old Ranbaxy hand having headed several key departments in the company earlier, was brought back from Glenmark Pharma to head the India operations in 2013. When contacted, he declined comment, while a Sun Pharma spokesperson said that the company does not comment on people movements. 
 
Sun Pharma has executed three rounds of manpower rationalisation over the past few months, starting from the top-most level of president, percolating to vice-presidents and directors in the latest round. In the latest round, over a dozen top executives have been asked to leave the company, making it one of the biggest manpower rejigs in recent times. 
 
“The massive manpower restructuring was done only after April, when all the regulatory clearances had come for Sun Pharma-Ranbaxy merger”, an industry expert said. 
 
Sun Pharma completed the $4-billion acquisition of Ranbaxy in March, after the deal was announced in April last year. After taking charge, Sun Pharma made it a six-day week in Ranbaxy from a five-day one, and introduced frugal policies for domestic and international travel, the source added. 
 
By Rupali Mukherjee
 

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend